PRTN3 and rheumatoid arthritis: A prospective study was conducted in the United Kingdom (UK), in 2021, to assess 100 patients with RA who tested positive for ACPA and received either BNT162b2 or ChAdOx1 nCoV-19/AZD1222 vaccines.